Vanderbilt HIV Clinical Trials Unit

描述(由申请人提供)：艾滋病毒大流行是对健康和发展的最大持续威胁之一，在认识到它之后的30多年里。NIAID资助的临床试验网络在协调应对艾滋病毒/艾滋病领域的关键研究问题方面发挥了关键作用。拟议的范德比尔特临床试验单位(CTU)是范德比尔特大学和华盛顿大学之间的合作伙伴关系，由三个表现最好的现有临床研究网站(CRSS)组成，这三个网站跨越了艾滋病临床试验小组(ACTG)的治疗任务和艾滋病毒疫苗试验网络(HVTN)的疫苗任务。这是在Vanderbilt Treateutics CRS和Vanderbilt Vaccine CRS之间已经建立的合作伙伴关系的基础上建立的，并增加了与华盛顿大学治疗CRS的新合作伙伴关系。自1987-1988年这两个网络成立以来，后两个站点一直是这两个网络的成员。反恐联盟的领导人在包括人类基因组学和艾滋病毒疾病的神经学方面在内的领域为该网络作出了具有重大影响的独特的科学和方案贡献。展望未来，CTU将继续其方案影响的记录，利用Vanderbilt在生物医学信息学方面的机构实力，实施灵活、实时、可共享的信息学工具，以 优化CTU性能。该CTU还受益于与NIH其他主要项目的密切联系，包括Vanderbilt作为全国约60个临床和转化科学奖(CTSA)网络的协调中心、NIAID赞助的评估艾滋病的国际流行病学数据库(LeDEA)的全球七个地区以及leDEA拉丁美洲地区的七个国家的协调中心。在拟议的发现期内，范德比尔特CTU将为ACTG侧重于艾滋病毒/艾滋病、结核病和病毒性肝炎的科学优先事项做出重大贡献，并将为HVTN开发和测试安全有效的艾滋病毒疫苗这一重大科学优先事项做出重大贡献。

DESCRIPTION (provided by applicant): The HIV pandemic is one of the greatest ongoing threats to health and development, over 30 years past its recognition. The NIAID-funded Clinical Trials Networks have played critical roles in the coordinated response to key research questions in the HIV/AIDS field. The proposed Vanderbilt Clinical Trials Unit (CTU) is a partnership between Vanderbilt University and Washington University, comprising three top-performing incumbent Clinical Research Sites (CRSs) that span the therapeutics mission of the AIDS Clinical Trials Group (ACTG) and the vaccine mission of the HIV Vaccine Trials Network (HVTN). This builds upon the already established partnership between the Vanderbilt Therapeutics CRS and the Vanderbilt Vaccine CRS, and adds a new partnership with the Washington University Therapeutics CRS. The latter two sites have been members of the HVTN and ACTG since the inception of these Networks in 1987-1988. The leaders of this CTU have made high-impact, unique scientific and programmatic contributions to the Networks in areas that include human genomics and neurological aspects of HIV disease. Moving forward this CTU will continue its track record of programmatic impact by leveraging Vanderbilt's institutional strength in biomedical informatics to implement flexible, real-time, shareable informatics tools to optimize CTU performance. This CTU also benefits from close ties to other major NIH programs including Vanderbilt's roles as Coordinating Center for the nationwide network of approximately 60 Clinical and Translational Science Awards (CTSA), for the seven worldwide regions of the NIAID-sponsored International Epidemiologic Databases to Evaluate AIDS (leDEA), and for the seven countries of leDEA's Latin American region. During the proposed finding period the Vanderbilt CTU will make substantial contributions to the ACTG's scientific priorities focused on HIV/AIDS, tuberculosis, and viral hepatitis, and will make substantial contributions to the HVTN's major scientific priority of developing and testing a safe and effective vaccine for HIV.